Lonza Expands Cell-Biology Platform by Acquiring Simbiosys Biowares’ Preclinical Cell and Molecular Biology Group

October 13,2009 Basel, Switzerland

Lonza Group (SIX:LONN) announces that it has completed the acquisition of the preclinical cell and molecular biology assets of Simbiosys Biowares India Pvt. Ltd as of 13 October 2009. Simbiosys Biowares is a premier biology outsourcing company with core competencies in cell and molecular biology, and in clinical services. The company’s cell and molecular biology group specializes in primary cell isolation and tissue sourcing and in performing preclinical services to mid-size pharmaceutical companies. Simbiosys Biowares India Pvt. Ltd. is based in Bangalore, India, with approximately 40 employees, and is a subsidiary of Simbiosys Biowares Inc., a start-up company based in Dallas, Texas, USA.

“We are happy to acquire the preclinical cell and molecular biology group of Simbiosys Biowares India, as it is aligned with Lonza’s strategy to continue to develop its life-science platform and to expand its global cell-biology portfolio. The deal further strengthens Lonza’s position as a worldwide leader in cell discovery by integrating a unique service model into its portfolio and by continuing to develop the company’s activities”, comments Anja Fiedler, Head of Lonza Bioscience. “The skilled R&D staff nicely complements our existing R&D capabilities in Cell Discovery”.

Simbiosys Biowares India Pvt Ltd offers preclinical services in the areas of:\

  • Drug discovery services (includes lead validation and lead development using in-vitro and in-vivo ADME-Tox assays).
  • Molecular biology contract research services (including DNA amplification and cloning, DNA / RNA isolation, synthetic gene construction and quantitative PCR).
  • Biopharmaceutical services (includes process design optimization of fermentation technology for producing small-molecules, proteins and mAbs for therapeutic, diagnostic and research applications).

 

Commencing today, Lonza will initiate full integration of the activities of the cell and molecular biology group of Simbiosys Biowares India Pvt Ltd and welcomes its highly skilled employees to the Lonza organization.

 

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2008, Lonza had sales of CHF 2.937 billion. Further information can be found at www.lonza.com.

 

About Simbiosys Bioawares India Pvt. Ltd

Simbiosys Biowares India Pvt Ltd is a premier cell-biology platform company that leverages its core competencies in cell & molecular biology to offer complete and innovative solutions for application-specific verticals in the bioscience industries. Simbiosys group’s global presence spanning Dallas, Texas and Bangalore, India enables the company to combine the technology resources of the U.S. with the cost advantages of India. Our global R&D delivery model helps create unique value for customers. Further information can be found at www.simbiosys-biowares.com.

 

For further Information

Lonza Group Ltd
Head Corporate Communications
Michael Frizberg
Tel +41 61 316 8624
Fax +41 61 316 9624
michael.frizberg@lonza.com

Lonza Group Ltd
Media Relations
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com

Lonza Group Ltd
Investor Relations
Marcel Rosenast
Tel +41 61 316 8728
Fax +41 61 316 9728
marcel.rosenast@lonza.com

Browse All News
Bg